MGMichelle M. Gomes

Michelle M. Gomes

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Michelle M. Gomes has a total of 98 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Extracellular vesicle glycan profiling for pre-biopsy detection of prostate cancer

    by Trevor Enright, Randall J. Armstrong, Jane Lange, Kai Tao, Sinan Sabuncu, Brooke Stoddard, Emek Demir, Mark Garzotto, Michelle M. Gomes

  • Open Access

    Utilizing Two Electrokinetic Techniques on a Single Device for Detection of Extracellular Vesicle‐Associated Protease Activity

    by Ella Stimson, Delaney Shea, Michelle M. Gomes, Srivathsan Ranganathan, Sarah Mitchell, Jason Ware, Randall Armstrong, Christian Ross, Michael Heller, Stuart D. Ibsen

    Protease activity is an emerging biomarker for cancer detection as activity levels are often increased in tumor tissue compared to healthy tissue. Of particular interest is the activity of proteases carried by extracellular vesicle (EV) nanoparticles which are oversecreted by tumors into circulation. Current methods to analyze the activity of proteases bound to EVs require complex multi‐instrument sample processing to separate EVs from plasma to quantify protease activity. This makes EV‐based protease activity detection a challenge for diagnostic or point‐of‐care applications. Here, a method is reported that manipulates EV nanoparticles and charged molecular byproducts from protease activity using two different electrokinetic phenomena generated by a single electrode microarray within a microfluidic channel. Dielectrophoresis is first generated to recover EVs carrying active trypsin‐like proteases from human plasma followed by electrophoresis for subsequent analysis of peptide cleavage products indicating protease activity. This method demonstrates signal amplification through protease catalytic activity in combination with concentrating mechanisms of dielectrophoresis and electrophoresis. Using this approach, a significant difference in protease activity is observed between patients with pancreatic cancer and benign cysts. This demonstrates dual‐electrokinetic chip‐based technology as a useful tool to manipulate different sized and charged analytes in a single device enabling future clinical translation of EV‐based protease diagnostics.


  • Open Access

    A Computationally Guided Approach to Improve Expression of VHH Binders

    by Emine Sila Ozdemir, Jessica Tolley, Florian Goncalves, Michelle Gomes, Eli Wagnell, Bruce Branchaud, Viktoriya Dubrovskaya, Srivathsan V. Ranganathan

    The variable heavy chain fragments derived from camelid antibodies, called VHHs or nanobodies, have recently shown promise as high-affinity reagents. They offer higher stability compared to conventional antibodies and fragments thereof. Furthermore, their smaller size (~15–20 kDa) allows better targeting of molecules localized inside the cell and in crowded environments, like tissues and protein aggregates. Despite these advantages, nanobody clones screened using phage display can suffer from poor soluble expression, which we hypothesized is due to the presence of hydrophobic hotspots on their surface. In this work, we propose a novel, computationally guided workflow for screening and production of nanobody binders for optimized expression. After an initial round of phage display screens against our target (K-Ras), we modeled the lead candidates to generate spatial aggregation propensity (SAP) maps to highlight the hydrophobic hotspots with single amino acid resolution, which were subsequently used to guide mutagenesis of the binders for soluble expression. We followed two approaches to perform point hydrophilic mutations: (i) performing point hydrophilic mutations in the hydrophobic hotspots; (ii) combining point mutation resulting from a round of random mutagenesis that show favorable SAP scores. Both approaches led to a remarkable increase in soluble expression, which allowed production and characterization of their binding to their target (K-Ras) on soluble ELISA and biolayer interferometry. We observed that the latter approach resulted in clones with stronger binding affinity compared to the former approach. Our results emphasize the need to perform a round of random mutagenesis to identify point mutations, which can then be used in an in silico guided pipeline to identify the right combination of mutations for high soluble expression.


  • Open Access

    Publisher Correction: OregonFluor enables quantitative intracellular paired agent imaging to assess drug target availability in live cells and tissues

    by Lei G. Wang, Antonio R. Montaño, Jason R. Combs, Nathan P. McMahon, Allison Solanki, Michelle M. Gomes, Kai Tao, William H. Bisson, Dani A. Szafran, Kimberley S. Samkoe, et al.


  • Open Access

    Data from Computational Modeling of TP63–TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics

    by E. Sila Ozdemir, Michelle M. Gomes, Jared M. Fischer

    Tumor protein p63 (TP63) is a member of the TP53 protein family that are important for development and in tumor suppression. Unlike TP53, TP63 is rarely mutated in cancer, but instead different TP63 isoforms regulate its activity. TA isoforms (TAp63) act as tumor suppressors, whereas ΔN isoforms are strong drivers of squamous or squamous-like cancers. Many of these tumors become addicted to ΔN isoforms and removal of ΔN isoforms result in cancer cell death. Furthermore, some TP53 conformational mutants (TP53CM) gain the ability to interact with TAp63 isoforms and inhibit their antitumorigenic function, while indirectly promoting tumorigenic function of ΔN isoforms, but the exact mechanism of TP63–TP53CM interaction is unclear. The changes in the balance of TP63 isoform activity are crucial to understanding the transition between normal and tumor cells. Here, we modeled TP63–TP53CM complex using computational approaches. We then used our models to design peptides to disrupt the TP63–TP53CM interaction and restore antitumorigenic TAp63 function. In addition, we studied ΔN isoform oligomerization and designed peptides to inhibit its oligomerization and reduce their tumorigenic activity. We show that some of our peptides promoted cell death in a TP63 highly expressed cancer cell line, but not in a TP63 lowly expressed cancer cell line. Furthermore, we performed kinetic–binding assays to validate binding of our peptides to their targets. Our computational and experimental analyses present a detailed model for the TP63–TP53CM interaction and provide a framework for potential therapeutic peptides for the elimination of TP53CM cancer cells.

  • Open Access

    Data from Computational Modeling of TP63–TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics

    by E. Sila Ozdemir, Michelle M. Gomes, Jared M. Fischer

    Tumor protein p63 (TP63) is a member of the TP53 protein family that are important for development and in tumor suppression. Unlike TP53, TP63 is rarely mutated in cancer, but instead different TP63 isoforms regulate its activity. TA isoforms (TAp63) act as tumor suppressors, whereas ΔN isoforms are strong drivers of squamous or squamous-like cancers. Many of these tumors become addicted to ΔN isoforms and removal of ΔN isoforms result in cancer cell death. Furthermore, some TP53 conformational mutants (TP53CM) gain the ability to interact with TAp63 isoforms and inhibit their antitumorigenic function, while indirectly promoting tumorigenic function of ΔN isoforms, but the exact mechanism of TP63–TP53CM interaction is unclear. The changes in the balance of TP63 isoform activity are crucial to understanding the transition between normal and tumor cells. Here, we modeled TP63–TP53CM complex using computational approaches. We then used our models to design peptides to disrupt the TP63–TP53CM interaction and restore antitumorigenic TAp63 function. In addition, we studied ΔN isoform oligomerization and designed peptides to inhibit its oligomerization and reduce their tumorigenic activity. We show that some of our peptides promoted cell death in a TP63 highly expressed cancer cell line, but not in a TP63 lowly expressed cancer cell line. Furthermore, we performed kinetic–binding assays to validate binding of our peptides to their targets. Our computational and experimental analyses present a detailed model for the TP63–TP53CM interaction and provide a framework for potential therapeutic peptides for the elimination of TP53CM cancer cells.

  • Open Access

    Supplementary Data from Computational Modeling of TP63–TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics

    by E. Sila Ozdemir, Michelle M. Gomes, Jared M. Fischer

    Supplementary Data from Computational Modeling of TP63–TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics

  • OregonFluor enables quantitative intracellular paired agent imaging to assess drug target availability in live cells and tissues

    by Lei G. Wang, Antonio R. Montaño, Jason R. Combs, Nathan P. McMahon, Allison Solanki, Michelle M. Gomes, Kai Tao, William H. Bisson, Dani A. Szafran, Kimberley S. Samkoe, et al.

    Non-destructive fluorophore diffusion across cell membranes to provide an unbiased fluorescence intensity readout is critical for quantitative imaging applications in live cells and tissues. Commercially available small-molecule fluorophores have been engineered for biological compatibility, imparting high water solubility by modifying rhodamine and cyanine dye scaffolds with multiple sulfonate groups. The resulting net negative charge, however, often renders these fluorophores cell-membrane-impermeant. Here we report the design and development of our biologically compatible, water-soluble and cell-membrane-permeable fluorophores, termed OregonFluor (ORFluor). By adapting previously established ratiometric imaging methodology using bio-affinity agents, it is now possible to use small-molecule ORFluor-labelled therapeutic inhibitors to quantitatively visualize their intracellular distribution and protein target-specific binding, providing a chemical toolkit for quantifying drug target availability in live cells and tissues.


  • Computational Modeling of TP63–TP53 Interaction and Rational Design of Inhibitors: Implications for Therapeutics

    by E. Sila Ozdemir, Michelle M. Gomes, Jared M. Fischer

    Tumor protein p63 (TP63) is a member of the TP53 protein family that are important for development and in tumor suppression. Unlike TP53, TP63 is rarely mutated in cancer, but instead different TP63 isoforms regulate its activity. TA isoforms (TAp63) act as tumor suppressors, whereas ΔN isoforms are strong drivers of squamous or squamous-like cancers. Many of these tumors become addicted to ΔN isoforms and removal of ΔN isoforms result in cancer cell death. Furthermore, some TP53 conformational mutants (TP53CM) gain the ability to interact with TAp63 isoforms and inhibit their antitumorigenic function, while indirectly promoting tumorigenic function of ΔN isoforms, but the exact mechanism of TP63–TP53CM interaction is unclear. The changes in the balance of TP63 isoform activity are crucial to understanding the transition between normal and tumor cells. Here, we modeled TP63–TP53CM complex using computational approaches. We then used our models to design peptides to disrupt the TP63–TP53CM interaction and restore antitumorigenic TAp63 function. In addition, we studied ΔN isoform oligomerization and designed peptides to inhibit its oligomerization and reduce their tumorigenic activity. We show that some of our peptides promoted cell death in a TP63 highly expressed cancer cell line, but not in a TP63 lowly expressed cancer cell line. Furthermore, we performed kinetic–binding assays to validate binding of our peptides to their targets. Our computational and experimental analyses present a detailed model for the TP63–TP53CM interaction and provide a framework for potential therapeutic peptides for the elimination of TP53CM cancer cells.